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 Central Asian Hemorrhagic Fever, 
 Hungribta (blood taking), 
 Khunymuny (nose bleeding), 
 Karakhalak (black death) 
 







Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic viral disease that is 
asymptomatic in infected animals, but a serious threat to humans. Human infections 
begin with nonspecific febrile symptoms, but progress to a serious hemorrhagic 
syndrome with a high case fatality rate. Although the causative virus is often 
transmitted by ticks, animal-to-human and human-to-human transmission also occur. 
This disease is a particular threat to farmers and other agricultural workers, 
veterinarians, laboratory workers and hospital personnel.  
Crimean-Congo hemorrhagic fever is one of the most widely distributed viral 
hemorrhagic fevers. This disease occurs in much of Africa, the Middle East and Asia, 
as well as parts of Europe. Changes in climatic conditions could expand the range of 
its tick vectors, and increase the incidence of disease. The CCHF virus is also a 
potential bioterrorist agent; it has been listed in the U.S. as a CDC/NIAID Category C 
priority pathogen.  
Etiology 
Crimean-Congo hemorrhagic fever is caused by Crimean-Congo hemorrhagic 
fever virus (CCHFV). This virus is a member of the genus Nairovirus in the family 
Bunyaviridae. It belongs to the CCHF serogroup. 
Although early serological studies revealed very few differences between strains 
of CCHFV, nucleic acid sequence analysis has demonstrated extensive genetic 
diversity, particularly between viruses from different geographic regions.  
Geographic Distribution 
CCHFV is widespread in Africa, the Middle East and Asia. It has also been 
found in parts of Europe including southern portions of the former USSR (Crimea, 
Astrakhan, Rostov, Uzbekistan, Kazakhstan, Tajikistan), Turkey, Bulgaria, Greece, 
Albania and Kosovo province of the former Yugoslavia. Limited serological evidence 
suggests that CCHFV might also occur in parts of Hungary, France and Portugal. The 
occurrence of this virus is correlated with the distribution of Hyalomma spp., the 
principal tick vectors. 
Transmission 
CCHFV usually circulates between asymptomatic animals and ticks in an 
enzootic cycle. This virus has been found in at least 31 species of ticks, including 
seven genera of the family Ixodidae (hard ticks). Members of the genus Hyalomma 
seem to be the principal vectors. Transovarial, transstadial and venereal transmission 
occur in this genus. Hyalomma marginatum marginatum is particularly important as a 
vector in Europe, but CCHFV is also found in Hyalomma anatolicum anatolicum and 
other Hyalomma spp. Other ixodid ticks including members of the genera 
Rhipicephalus, Boophilus, Dermacentor and Ixodes may also transmit the virus 
locally. Although CCHFV has been reported in other families of invertebrates, these 
species may not be biological vectors; the virus may have been ingested in a recent 
blood meal. In one study, CCHFV was reported from a biting midge (Culicoides 
spp.). It has also been found in two species of Argasidae (soft ticks); however, 
experimental infections suggest that CCHFV does not replicate in this family of ticks.  
Many species of mammals can transmit CCHFV to ticks when they are viremic. 
Small vertebrates such as hares and hedgehogs, which are infested by immature ticks, 
may be particularly important as amplifying hosts. With a few exceptions, birds seem 
to be refractory to infection; however, they may act as mechanical vectors by 
transporting infected ticks. Migratory birds might spread the virus between distant 
geographic areas. 
Humans become infected through the skin and by ingestion. Aerosol transmission 
was suspected in a few cases in Russia. Sources of exposure include being bitten by a 
tick, crushing an infected tick with bare skin, contacting animal blood or tissues and 
drinking unpasteurized milk. Human-to-human transmission occurs, particularly 
when skin or mucous membranes are exposed to blood during hemorrhages or tissues  
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during surgery. CCHFV is stable for up to 10 days in blood 
kept at 40°C (104°F). Possible horizontal transmission has 
been reported from a mother to her child.   
Disinfection 
CCHFV can be inactivated by disinfectants including 
1% hypochlorite and 2% glutaraldehyde. It is also 
destroyed by heating at 56°C (133°F) for 30 min.  
Infections in Humans 
Incubation Period 
The incubation period is influenced by the route of 
exposure. Infections acquired via tick bites usually become 
apparent after 1 to 3 days; the longest incubation period 
reported by this route is nine days. Exposure to blood or 
tissues usually results in a longer incubation period. Current 
estimates suggest that these infections become apparent, on 
average, after 5 to 6 days, but incubation periods up to 13 
days are known. 
Clinical Signs 
The first sign of Crimean-Congo hemorrhagic fever is 
a sudden onset of fever and other nonspecific symptoms 
including chills, severe headache, dizziness, photophobia, 
neck pain, myalgia and arthralgia. The fever may be very 
high. Gastrointestinal symptoms including nausea, 
vomiting, non-bloody diarrhea and abdominal pain are also 
common. Sharp mood changes, confusion and aggression 
have been reported in some cases. Cardiovascular changes 
such as bradycardia and low blood pressure can also occur. 
This early stage of disease is called the prehemorrhagic 
phase. It is followed, after several days, by the hemorrhagic 
phase.  
The hemorrhagic phase develops suddenly. It is usually 
short, lasting on average 2 to 3 days. A petechial rash may 
be the first symptom. The rash is followed by petechiae, 
ecchymoses and large bruises on the skin and mucous 
membranes. Hematemesis, melena, epistaxis, hematuria, 
hemoptysis and bleeding from venipuncture sites are also 
common. Bleeding can occur in other locations, including 
the brain. In one case, internal bleeding mimicked acute 
appendicitis. Hepatitis occurs in some patients, and may 
result in jaundice and hepatomegaly. Splenomegaly can 
also be seen. Some patients die from hemorrhages, 
hemorrhagic pneumonia or cardiovascular disturbances.  
In patients who survive, recovery begins 10 to20 days 
after the onset of illness. The convalescent phase is 
characterized by generalized weakness, a weak pulse and 
tachycardia. Other symptoms including sweating, dryness 
of the mouth, headache, dizziness, nausea, poor appetite, 
labored breathing, polyneuritis, poor vision, loss of hearing, 
and memory loss have also be seen. Some patients 
temporarily lose all of their hair. Hepatorenal insufficiency 
has been reported in some countries but not others. 
Recovery is usually complete but slow, and can take up to a 
year. Subclinical infections can occur, but are thought to be 
uncommon. Mild febrile cases without hemorrhages are 
also seen. 
Communicability 
CCHFV is present in blood, body fluids and tissues 
from affected patients; hemorrhages are an important 
source of exposure for other people, particularly family 
members and healthcare workers. Possible horizontal 
transmission has been reported from a mother to her child. 
Diagnostic Tests 
Crimean-Congo hemorrhagic fever can be diagnosed 
by isolating CCHFV from blood, plasma or tissues. At 
autopsy, the virus is most likely to be found in the lung, 
liver, spleen, bone marrow, kidney and brain. CCHFV can 
be isolated in a variety of cell lines including SW-13, Vero, 
LLC-MK2 and BHK-21 cells. Cell cultures can only detect 
high concentrations of the virus, and this technique is most 
useful during the first five days of illness. Animal 
inoculation into newborn mice is more sensitive than 
culture, and can detect the virus for a longer period. 
CCHFV is identified by indirect immunofluorescence or 
reverse transcription-polymerase chain reaction (RT-PCR) 
assays. Virus isolation must be carried out in maximum 
biocontainment laboratories (BSL-4).  
Crimean-Congo hemorrhagic fever is often diagnosed by 
RT-PCR on blood samples. This technique is highly 
sensitive. However, due to the genetic variability in CCHFV 
strains, a single set of primers cannot detect all virus variants, 
and most RT-PCR assays are either designed to detect local 
variants or lack sensitivity. A real-time RT-PCR assay that 
can detect numerous variants has recently been published. 
Viral antigens can be identified with enzyme-linked 
immunoassay (ELISA) or immunofluorescence, but this test 
is less sensitive than PCR. 
Crimean-Congo hemorrhagic fever can also be 
diagnosed by serology. Tests detect CCHFV-specific IgM, 
or a rise in IgG titers in paired acute and convalescent sera. 
IgG and IgM can usually be found with indirect 
immunofluorescence or ELISA after 7-9 days of illness. 
Other serologic tests such as complement fixation and 
hemagglutination inhibition were used to diagnose 
Crimean-Congo hemorrhagic fever in the past, but lacked 
sensitivity. In fatal cases, patients generally die without 
developing antibodies.  
Treatment 
Treatment is mainly supportive. Ribavirin is used in 
some cases. Observational studies in humans and studies in 
experimentally infected mice support the use of this drug; 
however, no randomized human clinical trials have been 
published. Passive immunotherapy with hyperimmune 
serum has been tested in a few cases, but the value of this 
treatment is controversial.  
 
Crimean-Congo Hemorrhagic Fever 
Last Updated: August 2007 © 2007 page 3 of 4 
Prevention 
In endemic regions, prevention depends on avoiding 
bites from infected ticks and contact with infected blood or 
tissues. 
Measures to avoid tick bites include tick repellents, 
environmental modification (brush removal, insecticides), 
avoidance of tick habitat and regular examination of 
clothing and skin for ticks. Clothing should be chosen to 
prevent tick attachment; long pants tucked into boots and 
long-sleeved shirts are recommended. Acaricides can be 
used on livestock and other domesticated animals to control 
ticks, particularly before slaughter or export.  
Protective clothing and gloves should be worn 
whenever skin or mucous membranes could be exposed to 
viremic animals, particularly when blood and tissues are 
handled. Unpasteurized milk should not be drunk. In meat, 
CCHFV is usually inactivated by post-slaughter 
acidification. It is also killed by cooking. 
Strict universal precautions are necessary when caring 
for human patients. These recommendations include barrier 
nursing, isolation and the use of gloves, gowns, face-shields 
and goggles with side shields. Prophylactic treatment with 
ribavirin has occasionally been used after high-risk 
exposures. Safe burial practices, including the use of 1:10 
liquid bleach solution as a disinfectant, have been 
published. Laboratory workers must follow stringent 
biosafety precautions. 
An inactivated vaccine from mouse brains has been 
used in the former Soviet Union and Bulgaria. In most 
countries, no vaccine is available. 
Morbidity and Mortality 
Climatic factors can influence the numbers of ticks in 
the environment and the incidence of disease. In some 
countries, Crimean-Congo hemorrhagic fever tends to be 
seasonal. This disease is most common in Iran during 
August and September, and in Pakistan from March to May 
and August to October.  
Most cases are the result of occupational exposure. 
CCHF is particularly common in farmers, shepherds, 
veterinarians, abattoir workers and laboratory workers. 
Healthcare workers are also at high risk, particularly after 
exposure to patients’ blood. During one nosocomial 
outbreak at a hospital in South Africa, 33% of medical 
personnel exposed via needlestick injuries became ill. 
Approximately 9% of those who had other forms of contact 
with infected blood also developed CCHF. In the general 
public, activities that increase tick exposure such as hiking 
and camping increase the risk of infection. 
The average case fatality rate is 30-50%, but mortality 
rates from 10% to 80% have been reported in various 
outbreaks. The mortality rate is usually higher for 
nosocomial infections than after tick bites; this may be 
related to the virus dose. Geographic location also seems to 
influence the death rate. Particularly high mortality rates 
have been reported in some outbreaks from the United Arab 
Emirates (73%) and China (80%). Geographic differences 
in viral virulence have been suggested, but are unproven. 
The mortality rate may also be influenced by the 
availability of rigorous supportive treatment in area 
hospitals. 
Infections in Animals 
Species Affected 
CCHFV can be found in many species of wild and 
domesticated mammals including small animals that serve 
as hosts for immature ticks, and large herbivores that act as 
hosts for mature ticks. CCHFV has been isolated from a 
number of species including cattle, sheep, goats, hares, 
hedgehogs, dogs and mice (Mastomys spp.). Antibodies 
have been reported in horses, donkeys, pigs, rhinoceroses, 
giraffes, buffalo and other mammalian species. Most 
species of birds are seronegative and are thought to be 
resistant to infection; however, antibodies can be found in 
ostriches, and these animals become viremic after 
experimental inoculation. Low CCHFV viremia was also 
reported from an experimentally infected blue-helmeted 
guinea fowl (Numidia meleagris), and antibodies have been 
reported in a magpie. A red-beaked hornbill and a glossy 
starling became seropositive after experimental infection, 
but viremia did not occur. Although immature Hyalomma 
anatolicum ticks sometimes feed on reptiles, antibodies to 
CCHFV have only been reported from one reptile, a tortoise 
from Tadzhikistan. 
Incubation Period/ Clinical Signs 
CCHFV infections are asymptomatic in animals other 
than experimentally inoculated newborn rodents (laboratory 
mice, rats and Syrian hamsters). The only symptom in 
experimentally infected sheep and cattle was a transient, 
mild elevation in body temperature. 
Communicability 
Mammals become viremic and can transmit CCHFV in 
their blood and tissues. Domesticated ruminants including 
cattle, sheep and goats are viremic for one week after 
experimental infection. Most species of birds seem to be 
resistant to infection, but in ostriches, CCHFV can be found 
in blood for 1 to 4 days and in visceral organs for up to five 
days after experimental infection. 
Post Mortem Lesions 
No lesions have been reported except in newborn 
rodents. 
Diagnostic Tests 
Serology can identify animals that have been infected 
or exposed to CCHFV. An IgG ELISA can detect 
antibodies for the remainder of the animal’s life; other tests, 
including complement fixation and indirect fluorescent 
antibody, usually detect antibodies for shorter periods. 
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Viremia can be recognized by virus isolation and other 
techniques (see ‘Diagnostic Tests’ section under Human 
Infections), but these tests are not used diagnostically. 
Prevention 
Acaricides can be used on animals to control ticks, 
particularly before slaughter or export. Human outbreaks 
have occurred after exposure to infected ostriches during 
slaughter; these infections seem to be preventable by 
keeping the birds free of ticks for 14 days before slaughter. 
In some countries, ostriches are subject to a 30-day pre-
slaughter quarantine period at export facilities. 
Morbidity and Mortality 
Large herbivores have the highest seroprevalence to 
CCHFV. Seroprevalence rates of 13–36% have been 
reported in some studies, while others suggest that more 
than 50% of adult livestock in endemic regions have 
antibodies. Animals carry CCHFV asymptomatically. 
Deaths occur only in newborn rodents. 
Internet Resources 
Centers for Disease Control and Prevention (CDC). 





Public Health Agency of Canada. Material Safety 
Data Sheets 
http://www.phac-aspc.gc.ca/msds-ftss/index.html  
The Merck Manual  
http://www.merck.com/pubs/mmanual/  
The Merck Veterinary Manual 
http://www.merckvetmanual.com/mvm/index.jsp  
World Health Organization. Crimean-Congo Haemorrhagic 
Fever Fact Sheet 
http://www.who.int/mediacentre/factsheets/fs208/en/  
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